JP2018518151A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518151A5
JP2018518151A5 JP2017550485A JP2017550485A JP2018518151A5 JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5 JP 2017550485 A JP2017550485 A JP 2017550485A JP 2017550485 A JP2017550485 A JP 2017550485A JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5
Authority
JP
Japan
Prior art keywords
seq
antibody
acid sequence
isolated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017550485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024357 external-priority patent/WO2016160620A2/en
Publication of JP2018518151A publication Critical patent/JP2018518151A/ja
Publication of JP2018518151A5 publication Critical patent/JP2018518151A5/ja
Withdrawn legal-status Critical Current

Links

JP2017550485A 2015-03-27 2016-03-25 B7−h4発現充実性腫瘍を処置するためのcar t細胞 Withdrawn JP2018518151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139592P 2015-03-27 2015-03-27
US62/139,592 2015-03-27
PCT/US2016/024357 WO2016160620A2 (en) 2015-03-27 2016-03-25 Car t-cells for the treatment of b7-h4 expressing solid tumors

Publications (2)

Publication Number Publication Date
JP2018518151A JP2018518151A (ja) 2018-07-12
JP2018518151A5 true JP2018518151A5 (enExample) 2019-05-09

Family

ID=57007182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550485A Withdrawn JP2018518151A (ja) 2015-03-27 2016-03-25 B7−h4発現充実性腫瘍を処置するためのcar t細胞

Country Status (8)

Country Link
US (1) US20180118831A1 (enExample)
EP (1) EP3274369A4 (enExample)
JP (1) JP2018518151A (enExample)
CN (1) CN107531782A (enExample)
AU (1) AU2016243126A1 (enExample)
CA (1) CA2981143A1 (enExample)
IL (1) IL254700A0 (enExample)
WO (1) WO2016160620A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10814011B1 (en) 2017-06-16 2020-10-27 Nantbio, Inc. Anti-B7-H4 antibodies and methods
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
BR112020015736A2 (pt) * 2018-02-11 2020-12-08 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2020242794B2 (en) * 2019-03-21 2024-02-01 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-B7S1 polypeptides and their use
IL283568B2 (en) * 2019-08-01 2025-01-01 Immunitybio Inc NK–92 cells modified with a chimeric antigen receptor against B7–H4
WO2021231959A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN113156120B (zh) * 2021-03-26 2022-03-25 中国医学科学院北京协和医院 B7h4在制备子宫内膜癌分子分型试剂及系统中的应用
EP4389768A4 (en) * 2021-08-18 2025-06-25 Harbour Biomed (Shanghai) Co., Ltd ANTI-B7-H4 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 addl 항체 및 그 용도
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
JP5941841B2 (ja) * 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
US9422351B2 (en) * 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
SG11201502757QA (en) * 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
MX2015010777A (es) * 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
EP3037819A4 (en) * 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus

Similar Documents

Publication Publication Date Title
JP2018511319A5 (enExample)
KR102924006B1 (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
Fisher et al. Generation and preclinical characterization of an antibody specific for SEMA4D
TWI878541B (zh) 抗cldn18.2抗體及其診斷用途
JP2018524973A5 (enExample)
CN112189021A (zh) 抗b7-h3抗体及其用途
JP2012012402A5 (enExample)
CN111995682B (zh) 抗人SIRPα单克隆抗体及其用途
JP2018518152A5 (enExample)
JP2013506428A5 (enExample)
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2014527398A5 (enExample)
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
KR20190034236A (ko) 항 b7-h4 항체
JP2018505681A5 (enExample)
JP2020513769A (ja) 抗lair1抗体およびその使用
JP2022548777A5 (enExample)
CN111620949A (zh) 结合人lag-3的抗体、其制备方法和用途
WO2018162944A1 (en) Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
CN118108853A (zh) Cd47/4-1bb结合蛋白及其医药用途
JPWO2014192974A1 (ja) 抗lgr6抗体を含む癌の検出用又は診断用試薬
JPWO2010117059A1 (ja) 形質細胞の腫瘍性増殖をきたす疾患の治療薬
JP7082112B2 (ja) 抗gpr20抗体
CN113527484A (zh) 抗cd47单克隆抗体
JP2025506203A5 (enExample)